Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phosphoproteomics predict response to midostaurin plus chemotherapy in independent cohorts of FLT3-mutated acute myeloid leukaemia.
Borek WE, Nobre L, Pedicona SF, Campbell AE, Christopher JA, Nawaz N, Perkins DN, Moreno-Cardoso P, Kelsall J, Ferguson HR, Patel B, Gallipoli P, Arruda A, Ambinder AJ, Thompson A, Williamson A, Ghiaur G, Minden MD, Gribben JG, Britton DJ, Cutillas PR, Dokal AD. Borek WE, et al. Among authors: ambinder aj. EBioMedicine. 2024 Sep 17;108:105316. doi: 10.1016/j.ebiom.2024.105316. Online ahead of print. EBioMedicine. 2024. PMID: 39293215 Free article.
Favorable outcomes in MDS and oligoblastic AML-MR after reduced-intensity conditioning allogeneic bone marrow transplantation with post-transplantation cyclophosphamide.
Sinanidis I, Hochman MJ, Tsai HL, Randall MP, Bonilla B, Varadhan R, Ambinder AJ, Jones RJ, DeZern AE, Karantanos T. Sinanidis I, et al. Among authors: ambinder aj. Bone Marrow Transplant. 2024 Aug;59(8):1178-1180. doi: 10.1038/s41409-024-02299-y. Epub 2024 May 7. Bone Marrow Transplant. 2024. PMID: 38714755 No abstract available.
Persistent IDH mutations are not associated with increased relapse or death in patients with IDH-mutated acute myeloid leukemia undergoing allogeneic hematopoietic cell transplant with post-transplant cyclophosphamide.
Ravindra N, Dillon LW, Gui G, Smith M, Gondek LP, Jones RJ, Corner A, Hourigan CS, Ambinder AJ. Ravindra N, et al. Among authors: ambinder aj. Bone Marrow Transplant. 2024 Mar;59(3):428-430. doi: 10.1038/s41409-023-02189-9. Epub 2024 Jan 5. Bone Marrow Transplant. 2024. PMID: 38182672 No abstract available.
Persistent IDH mutations are not associated with increased relapse or death in patients with IDH-mutated acute myeloid leukemia undergoing allogeneic hematopoietic cell transplant with post-transplant cyclophosphamide.
Ravindra N, Dillon LW, Gui G, Smith M, Gondek LP, Jones RJ, Corner A, Hourigan CS, Ambinder AJ. Ravindra N, et al. Among authors: ambinder aj. medRxiv [Preprint]. 2023 Aug 21:2023.08.14.23294087. doi: 10.1101/2023.08.14.23294087. medRxiv. 2023. Update in: Bone Marrow Transplant. 2024 Mar;59(3):428-430. doi: 10.1038/s41409-023-02189-9. PMID: 37662423 Free PMC article. Updated. Preprint.
Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease.
Sanber K, Ye K, Tsai HL, Newman M, Webster JA, Gojo I, Ghiaur G, Prince GT, Gondek LP, Smith BD, Levis MJ, DeZern AE, Ambinder AJ, Dalton WB, Jain T. Sanber K, et al. Among authors: ambinder aj. Leuk Lymphoma. 2023 Apr;64(4):846-855. doi: 10.1080/10428194.2023.2173523. Epub 2023 Feb 6. Leuk Lymphoma. 2023. PMID: 36744656
Reply: Not All Inhaled Medicines Are Equal.
Rabin AS, Harlan EA, Ambinder AJ. Rabin AS, et al. Among authors: ambinder aj. Ann Am Thorac Soc. 2022 Nov;19(11):1949-1950. doi: 10.1513/AnnalsATS.202208-670LE. Ann Am Thorac Soc. 2022. PMID: 35939822 Free PMC article. No abstract available.
19 results